AVEO Pharmaceuticals Inc.

6.87+0.1300+1.93%Vol 299.72K1Y Perf 20.07%
Sep 23rd, 2021 13:15 DELAYED
BID6.86 ASK6.87
Open6.77 Previous Close6.74
Pre-Market6.75 After-Market-
 0.01 0.15%  - -
Target Price
20.00 
Analyst Rating
Strong Buy 1.00
Potential %
191.55 
Finscreener Ranking
★★★+     52.50
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★+     43.49
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★★+     49.47
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
14.45 
Earnings Rating
Buy
Market Cap236.15M 
Earnings Date
8th Nov 2021
Alpha0.02 Standard Deviation0.36
Beta1.20 

Today's Price Range

6.777.06

52W Range

4.9518.24

5 Year PE Ratio Range

-20.30-4.40

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
1.81%
1 Month
13.85%
3 Months
-1.75%
6 Months
-22.44%
1 Year
20.07%
3 Years
-76.43%
5 Years
-25.11%
10 Years
-95.81%

TickerPriceChg.Chg.%
AVEO6.870.13001.93
AAPL146.690.84000.58
GOOG2 839.1520.38000.72
MSFT299.891.31000.44
XOM57.121.91003.46
WFC48.060.98002.08
JNJ165.731.80001.10
FB345.802.59000.75
GE103.985.44005.52
JPM161.465.55003.56
Financial StrengthValueIndustryS&P 500US Markets
6.20
6.40
0.35
0.55
-19.80
Leverage Ratio 1.80
ProfitabilityValueIndustryS&P 500US Markets
93.10
-379.10
-378.80
-515.80
-13.53
RevenueValueIndustryS&P 500US Markets
13.96M
0.41
16.69
14.24
Earnings HistoryEstimateReportedSurprise %
Q02 2021-0.47-0.48-2.13
Q01 2021-0.55-0.72-30.91
Q04 2020-0.38-0.44-15.79
Q03 2020-0.24-0.33-37.50
Q02 2020-0.51-0.4217.65
Q01 2020-0.50-0.52-4.00
Q04 2019-0.58-0.2851.72
Q03 20190.101.00900.00
Earnings Per EndEstimateRevision %Trend
9/2021 QR-0.362.70Positive
12/2021 QR-0.1855.00Positive
12/2021 FY-1.644.09Positive
12/2022 FY-0.3025.00Positive
Next Report Date8th Nov 2021
Estimated EPS Next Report-0.36
Estimates Count3
EPS Growth Next 5 Years %-
Volume Overview
Volume299.72K
Shares Outstanding34.37M
Shares Float30.34M
Trades Count1.66K
Dollar Volume2.74M
Avg. Volume1.21M
Avg. Weekly Volume673.33K
Avg. Monthly Volume385.76K
Avg. Quarterly Volume449.50K

AVEO Pharmaceuticals Inc. (NASDAQ: AVEO) stock closed at 6.74 per share at the end of the most recent trading day (a 1.97% change compared to the prior day closing price) with a volume of 248.90K shares and market capitalization of 236.15M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 19 people. AVEO Pharmaceuticals Inc. CEO is Michael P. Bailey.

The one-year performance of AVEO Pharmaceuticals Inc. stock is 20.07%, while year-to-date (YTD) performance is 16.81%. AVEO stock has a five-year performance of -25.11%. Its 52-week range is between 4.95 and 18.24, which gives AVEO stock a 52-week price range ratio of 14.45%

AVEO Pharmaceuticals Inc. currently has a PE ratio of -3.50, a price-to-book (PB) ratio of 3.93, a price-to-sale (PS) ratio of 16.22, a price to cashflow ratio of 19.50, a PEG ratio of 2.32, a ROA of -57.70%, a ROC of -68.97% and a ROE of -100.29%. The company’s profit margin is -13.53%, its EBITDA margin is -378.80%, and its revenue ttm is $13.96 Million , which makes it $0.41 revenue per share.

Of the last four earnings reports from AVEO Pharmaceuticals Inc., there were 0 positive earnings surprise and 4 negative earnings surprise. The company has EPS estimate of $-0.36 for the next earnings report. AVEO Pharmaceuticals Inc.’s next earnings report date is 08th Nov 2021.

The consensus rating of Wall Street analysts for AVEO Pharmaceuticals Inc. is Strong Buy (1), with a target price of $20, which is +191.55% compared to the current price. The earnings rating for AVEO Pharmaceuticals Inc. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

AVEO Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

AVEO Pharmaceuticals Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 12.17, ATR14 : 0.33, CCI20 : 112.67, Chaikin Money Flow : 0.02, MACD : 0.19, Money Flow Index : 33.66, ROC : 9.24, RSI : 58.77, STOCH (14,3) : 76.14, STOCH RSI : 0.46, UO : 56.87, Williams %R : -23.86), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of AVEO Pharmaceuticals Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
3 (100.00 %)
3 (100.00 %)
3 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

AVEO Pharmaceuticals Inc.

AVEO Pharmaceuticals Inc is a biopharmaceutical company dedicated to advancing a broad portfolio of targeted medicines for oncology and other areas of unmet medical need. The Company's aim is to retain North American rights to its oncology portfolio while securing partners in development and commercialization outside of North America. It is seeking to develop and commercialize its lead candidate tivozanib in North America as a treatment for advanced or metastatic renal cell carcinoma (RCC). It has outlicensed tivozanib (FOTIVDA) for oncology in Europe and other territories outside North America.

CEO: Michael P. Bailey

Telephone: +1 617 588-1960

Address: One Broadway, Cambridge 02142, MA, US

Number of employees: 19

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

64%36%

Bearish Bullish

61%39%

Bearish Bullish

67%33%

TipRanks News for AVEO

News

Stocktwits